MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma
Eun Young Kang(University of Calgary), Alexander Hein, Jesús García-Donás(Universidad San Pablo CEU), Constantina Mateoiu(University of Gothenburg), Derek S. Chiu(University of British Columbia), Neil Lambie(New South Wales Department of Health), F. Kommoss(Heidelberg University), Kunle Odunsi(University of Chicago), Esther Elishaev(University of Pittsburgh), Maria Lycke(University of Gothenburg), Marina Pavanello(Westmead Institute for Medical Research), Claus Høgdall(Copenhagen University Hospital), Lilian van‐Wagensveld(The Netherlands Cancer Institute), Robert A. Vierkant(Mayo Clinic), Liselore Loverix(VIB-KU Leuven Center for Cancer Biology), Adelyn Bolithon(Cancer Institute of New South Wales), Stacey J. Winham(Mayo Clinic), Michael S. Anglesio(University of British Columbia), Christiani Bisinotto(Universidade de São Paulo), Chiu-Chen Tseng(University of Southern California), Beyhan Ataseven(Kliniken Essen-Mitte), Sabine Heublein(Heidelberg University), Sarah E. Taylor(Magee-Womens Research Institute), Joshua Millstein(University of Southern California), Andreas du Bois(Kliniken Essen-Mitte), Arndt Hartmann(Universitätsklinikum Erlangen), Sergio Ruiz‐Llorente(Consejo Superior de Investigaciones Científicas), Alexander Olawaiye(Magee-Womens Hospital), Daniel W. Cramer(Brigham and Women's Hospital), Gordana Popović(The University of Sydney), Malcolm C. Pike(Kettering University), Janine M. Joseph(Roswell Park Comprehensive Cancer Center), Robert P. Edwards(Cancer Research UK Technology), Sebastian M. Armasu(Mayo Clinic in Florida), Mónica Yagüe-Fernández(Hospital Universitario HM Sanchinarro), Naoko Sasamoto(University of Washington), Philipp Harter(Kliniken Essen-Mitte), Diether Lambrechts(VIB-KU Leuven Center for Cancer Biology), Siel Olbrecht(The European Academy of Gynaecological Surgery), Katrina Tang(Prince of Wales Hospital), Thomas P. Conrads(Inova Health System), Aline Talhouk(University of British Columbia), Annalyn Da-Anoy(University of Calgary), Celeste Leigh Pearce(University of Southern California), Betty Leung(UNSW Sydney), Sanela Bilic, Chen Wang(Xiamen University), Yajue Huang(Mayo Clinic), Jenny Lester, Nicola S. Meagher(The University of Sydney)
Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
November 15, 2021
Cited by 23
Related Papers
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Intraepithelial CD8 <sup>+</sup> tumor-infiltrating lymphocytes and a high CD8 <sup>+</sup> /regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
|Proceedings of the National Academy of Sciences|2005|2.4k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
<i>ARID1A</i> Mutations in Endometriosis-Associated Ovarian Carcinomas
|New England Journal of Medicine|2010|1.7k
Genomic and Functional Approaches to Understanding Cancer Aneuploidy
|Cancer Cell|2018|1.2k